Armenia vs Lithuania: Share of the population living with HIV receiving antiretroviral therapy
Armenia
52.0%
in 2024
Lithuania
51.9%
in 2024
Armenia rank
123rd
Lithuania rank
124th
Share of the population living with HIV receiving antiretroviral therapy over time
- Armenia
- Lithuania
How they compare
Armenia currently reports 52.0% against 51.9% in Lithuania, a difference of 0.1%.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Lithuania ahead.
Armenia ranks 123rd and Lithuania ranks 124th of 149 countries.
Armenia has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Armenia | Lithuania | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0.0% | 0.0% | 0.0% | — |
| 2000s | 3.7% | 3.2% | 0.5% | Armenia |
| 2010s | 26.7% | 21.6% | 5.1% | Armenia |
| 2020s | 47.3% | 44.2% | 3.1% | Armenia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher share of the population living with hiv receiving antiretroviral therapy, Armenia or Lithuania?
- Armenia, at 52.0% against 51.9% in Lithuania as of 2024.
- What is the difference in share of the population living with hiv receiving antiretroviral therapy between Armenia and Lithuania?
- 0.1%, with Armenia ahead.
- How many years of comparable data are there for Armenia and Lithuania?
- 35 years are reported by both, from 1990 to 2024.
- How do Armenia and Lithuania rank globally for share of the population living with hiv receiving antiretroviral therapy?
- Armenia ranks 123rd and Lithuania ranks 124th of 149 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as Share of the population living with HIV receiving antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.